Coronavirus Drug Targets: Could Blocking RNA Contacts

What new coronavirus drug targets did researchers identify?

The study, published October 30 in Nature Communications, examined three SARS-CoV-2 proteins: NSP8, NSP12 and nucleocapsid, known as N. Using enhanced crosslinking and immunoprecipitation, or eCLIP, the team mapped where these proteins directly contacted viral RNA during infection. This approach reveals molecular interactions that might otherwise remain hidden when researchers investigate only predicted targets. [Original study](https://www.nature.com/articles/s41467-026-78788-z).

One finding linked NSP12, the enzyme that copies viral RNA, to an RNA region encoding part of NSP3. Another showed N binding near the beginning of the genome, supporting a role in regulating protein production. The study also linked N to a region that helps ribosomes change reading frames when making viral proteins. Together, these findings suggest several ways RNA interactions help coordinate infection. [Nature Communications](https://www.nature.com/articles/s41467-026-78788-z).

How could blocking RNA-protein interactions become a treatment?

To test that possibility, researchers used locked nucleic acids: short, chemically modified molecules designed to bind selected RNA sequences. Blocking the identified sites reduced viral replication in cultured cells, including human lung cells. This provides an early experimental reason to investigate the sites as drug targets. It does not show that administering these molecules to patients would produce the same effect. [UC San Diego research announcement](https://www.newswise.com/articles/rna-protein-interactions-reveal-new-coronavirus-drug-targets/?ad2f=1&aid=857733).

The strategy extends an established antiviral principle: disrupt machinery that the virus depends on. Remdesivir already targets viral RNA copying, while nirmatrelvir targets a viral enzyme needed to process proteins. RNA-directed molecules could offer another route to interfering with essential functions. Whether that route would improve treatment or complement existing medicines remains a question for future experiments. [UC San Diego research announcement](https://www.newswise.com/articles/rna-protein-interactions-reveal-new-coronavirus-drug-targets/?ad2f=1&aid=857733).

Could these targets lead to treatments that withstand new variants?

The researchers argue that interactions essential to viral function may be harder for the virus to change without a biological cost. Some relevant RNA sequences and proteins are conserved among coronaviruses, creating a rationale for exploring broader antiviral activity. However, conservation alone does not demonstrate that a medicine will work against multiple viruses or prevent drug resistance. [UC Riverside research report](https://news.ucr.edu/articles/2026/10/30/rna-protein-interactions-could-lead-new-coronavirus-drug-targets).

UC Riverside explicitly describes the experiments as cell-culture work and identifies animal studies as a necessary next step. The clinical implication is therefore limited: these findings nominate targets for further development. They do not establish dosing, safety or a reduction in hospitalization, and they provide no basis for replacing established COVID-19 treatment. [UC Riverside research report](https://news.ucr.edu/articles/2026/10/30/rna-protein-interactions-could-lead-new-coronavirus-drug-targets).